NASDAQ:AGLE - Aeglea Bio Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.55 +0.07 (+1.08 %) (As of 05/20/2019 12:37 PM ET)Previous Close$6.48Today's Range$6.3627 - $6.7652-Week Range$6.31 - $12.00Volume91,636 shsAverage Volume89,950 shsMarket Capitalization$188.97 millionP/E RatioN/ADividend YieldN/ABeta0.89 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB4104, a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocysteine; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Receive AGLE News and Ratings via Email Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGLE Previous Symbol CUSIPN/A CIK1636282 Webwww.aegleabio.com Phone512-942-2935Debt Debt-to-Equity RatioN/A Current Ratio10.74 Quick Ratio10.74Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.89 million Price / Sales48.58 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book1.63Profitability EPS (Most Recent Fiscal Year)($2.13) Net Income$-44,350,000.00 Net MarginsN/A Return on Equity-66.57% Return on Assets-59.79%Miscellaneous Employees61 Outstanding Shares28,850,000Market Cap$188.97 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions What is Aeglea Bio Therapeutics' stock symbol? Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE." How were Aeglea Bio Therapeutics' earnings last quarter? Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) issued its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.04. View Aeglea Bio Therapeutics' Earnings History. When is Aeglea Bio Therapeutics' next earnings date? Aeglea Bio Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Aeglea Bio Therapeutics. What price target have analysts set for AGLE? 3 brokers have issued 1 year target prices for Aeglea Bio Therapeutics' shares. Their predictions range from $14.00 to $21.00. On average, they expect Aeglea Bio Therapeutics' stock price to reach $17.50 in the next year. This suggests a possible upside of 169.2% from the stock's current price. View Analyst Price Targets for Aeglea Bio Therapeutics. What is the consensus analysts' recommendation for Aeglea Bio Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aeglea Bio Therapeutics. Has Aeglea Bio Therapeutics been receiving favorable news coverage? Media headlines about AGLE stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Aeglea Bio Therapeutics' key competitors? Some companies that are related to Aeglea Bio Therapeutics include ArQule (ARQL), Y-mAbs Therapeutics (YMAB), ChemoCentryx (CCXI), Arvinas (ARVN), Vectura Group (VEGPF), Aptorum Group (APM), ZIOPHARM Oncology (ZIOP), Intra-Cellular Therapies (ITCI), Lexicon Pharmaceuticals (LXRX), Emisphere Technologies (EMIS), Advanz Pharma (CXRXF), Akebia Therapeutics (AKBA), Organogenesis (ORGO), Crinetics Pharmaceuticals (CRNX) and CannTrust (CTST). What other stocks do shareholders of Aeglea Bio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea Bio Therapeutics investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), Puma Biotechnology (PBYI), AcelRx Pharmaceuticals (ACRX), Array Biopharma (ARRY), Bellicum Pharmaceuticals (BLCM), Dynavax Technologies (DVAX), Fate Therapeutics (FATE) and GW Pharmaceuticals PLC- (GWPH). Who are Aeglea Bio Therapeutics' key executives? Aeglea Bio Therapeutics' management team includes the folowing people: Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)Mr. Charles N. York II, CFO & VP (Age 42)Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 48)Mr. Eugene Sackett, VP of HR When did Aeglea Bio Therapeutics IPO? (AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Aeglea Bio Therapeutics' major shareholders? Aeglea Bio Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.17%), Jennison Associates LLC (2.69%), Renaissance Technologies LLC (1.57%), Dimensional Fund Advisors LP (1.56%), Goldman Sachs Group Inc. (1.40%) and Marshall Wace LLP (1.30%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart, Anthony G Quinn, Bioventures Ltd Novartis and Charles N York II. View Institutional Ownership Trends for Aeglea Bio Therapeutics. Which institutional investors are selling Aeglea Bio Therapeutics stock? AGLE stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Man Group plc, Morgan Stanley, Algert Global LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Aeglea Bio Therapeutics. Which institutional investors are buying Aeglea Bio Therapeutics stock? AGLE stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Marshall Wace LLP, BlackRock Inc., Dimensional Fund Advisors LP, Assenagon Asset Management S.A., Fosun International Ltd, Northern Trust Corp and Marshall Wace North America L.P.. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn and Charles N York II. View Insider Buying and Selling for Aeglea Bio Therapeutics. How do I buy shares of Aeglea Bio Therapeutics? Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aeglea Bio Therapeutics' stock price today? One share of AGLE stock can currently be purchased for approximately $6.50. How big of a company is Aeglea Bio Therapeutics? Aeglea Bio Therapeutics has a market capitalization of $187.53 million and generates $3.89 million in revenue each year. The biotechnology company earns $-44,350,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe. What is Aeglea Bio Therapeutics' official website? The official website for Aeglea Bio Therapeutics is http://www.aegleabio.com. How can I contact Aeglea Bio Therapeutics? Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected] MarketBeat Community Rating for Aeglea Bio Therapeutics (NASDAQ AGLE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 174 (Vote Outperform)Underperform Votes: 139 (Vote Underperform)Total Votes: 313MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: What is a Lock-Up Period? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.